| scholarly article | Q13442814 |
| P50 | author | Daniel J Murphy | Q47112024 |
| P2093 | author name string | S J Parsons | |
| M E Cox | |||
| P D Deeble | |||
| P2860 | cites work | Effects of serotonin on neurite outgrowth from thalamic neurons in vitro | Q48226550 |
| Bone morphogenetic protein-2 promotes dissociated effects on the number and differentiation of cultured ventral mesencephalic dopaminergic neurons | Q48281735 | ||
| Class III beta-tubulin isotype (beta III) in the adrenal medulla: I. Localization in the developing human adrenal medulla. | Q52189573 | ||
| Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor beta4 subunit gene. | Q52559253 | ||
| Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate | Q67701823 | ||
| A common nuclear signal transduction pathway activated by growth factor and cytokine receptors | Q70476706 | ||
| Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells | Q71674458 | ||
| Nicotine stimulates secretion of both catecholamines and acetylcholinesterase from cultured adrenal chromaffin cells | Q71690022 | ||
| Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia | Q71869756 | ||
| Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro | Q71955600 | ||
| Class III beta-tubulin isotype (beta III) in the adrenal medulla: II. Localization in primary human pheochromocytomas | Q74364440 | ||
| Class III beta-tubulin isotype (beta III) in the adrenal medulla: III. Differential expression of neuronal and glial antigens identifies two distinct populations of neuronal and glial-like (sustentacular) cells in the PC12 rat pheochromocytoma cell | Q74364445 | ||
| Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer | Q78225972 | ||
| Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium | Q83177003 | ||
| Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP | Q22008544 | ||
| Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells | Q24317507 | ||
| Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells | Q24319902 | ||
| Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR | Q28144113 | ||
| Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation | Q28288257 | ||
| Effect of phosphorylation on activities of Rap1A to interact with Raf-1 and to suppress Ras-dependent Raf-1 activation | Q28292424 | ||
| cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway | Q28611450 | ||
| Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells | Q29618480 | ||
| Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression | Q30304209 | ||
| c-Raf-mediated inhibition of epidermal growth factor-stimulated cell migration | Q30304264 | ||
| Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line | Q30305599 | ||
| A 42-kD tyrosine kinase substrate linked to chromaffin cell secretion exhibits an associated MAP kinase activity and is highly related to a 42-kD mitogen-stimulated protein in fibroblasts | Q30441235 | ||
| Induction of c-fos mRNA and AP-1 DNA-binding activity by cAMP in cooperation with either the adenovirus 243- or the adenovirus 289-amino acid E1A protein | Q30454143 | ||
| Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate | Q30471390 | ||
| Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells | Q30473045 | ||
| Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer | Q34340156 | ||
| Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer | Q35264411 | ||
| Interleukin-6 and its receptor: a paradigm for cytokines | Q35425050 | ||
| Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP | Q35436566 | ||
| Interleukin-6: structure-function relationships. | Q36280356 | ||
| Multiple sequence elements of a single functional class are required for cyclic AMP responsiveness of the mouse c-fos promoter | Q36762038 | ||
| Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma | Q39487932 | ||
| Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture | Q40870361 | ||
| Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . | Q40905632 | ||
| STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . | Q40905638 | ||
| STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. | Q40908937 | ||
| Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo | Q40922547 | ||
| Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. | Q41019559 | ||
| The cyclic adenosine monophosphate-dependent protein kinase (PKA) is required for the sustained activation of mitogen-activated kinases and gene expression by nerve growth factor | Q41045775 | ||
| Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations | Q41110192 | ||
| Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes. Functional interactions between Sp1 and the rat beta4 subunit gene promoter | Q41144513 | ||
| Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. | Q41159496 | ||
| Interleukin-6: a candidate mediator of human prostate cancer morbidity | Q41362792 | ||
| Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines | Q41469811 | ||
| Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. | Q41472510 | ||
| Interleukin 6 and its receptor: ten years later | Q41722189 | ||
| Integration of growth factor signals at the c-fos serum response element | Q42813969 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| interleukins | Q194908 | ||
| prostate neoplasm | Q56014511 | ||
| P304 | page(s) | 8471-8482 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells | |
| P478 | volume | 21 |
| Q42855019 | Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway |
| Q33291100 | Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells |
| Q53686355 | Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells. |
| Q44881419 | Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer |
| Q35191051 | Androgen-regulated formation and degradation of gap junctions in androgen-responsive human prostate cancer cells |
| Q34714834 | Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth |
| Q28539820 | Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells |
| Q64965191 | Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. |
| Q40605826 | Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells |
| Q39502690 | Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression |
| Q36639877 | Clinical implications of neuroendocrine differentiation in prostate cancer |
| Q28205761 | Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation |
| Q40409497 | Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian recombinant 6 histidine-tagged H2 relaxin |
| Q35945055 | EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt |
| Q55032457 | Effect of A549 neuroendocrine differentiation on cytotoxic immune response. |
| Q91584300 | Endocrine regulation of prostate cancer growth |
| Q37424118 | Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells |
| Q34792992 | Epigenetics wins over genetics: induction of differentiation in tumor cells |
| Q40160207 | Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation |
| Q42071191 | Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. |
| Q35634255 | G proteins in cancer: the prostate cancer paradigm |
| Q37564369 | GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. |
| Q90411797 | Highlight article: The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer |
| Q38421322 | Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells. |
| Q40177599 | Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6. |
| Q53277140 | Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. |
| Q49210539 | Interleukin-6 and Interferon-α Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States |
| Q38995864 | Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). |
| Q39819739 | Interleukin-6 regulates androgen synthesis in prostate cancer cells |
| Q35380936 | Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients |
| Q38796619 | Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells |
| Q24534726 | JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells |
| Q36879620 | LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling |
| Q42964565 | Loss of Prkar1a leads to Bcl-2 family protein induction and cachexia in mice. |
| Q40513840 | Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism |
| Q52714356 | MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. |
| Q24802614 | Mitogen Activated Protein kinase signal transduction pathways in the prostate |
| Q35191037 | Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus immediate-early gene expression from latency. |
| Q89622450 | Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression |
| Q33224548 | Molecular alterations in primary prostate cancer after androgen ablation therapy |
| Q37630578 | Molecular mechanisms of castration-resistant prostate cancer progression |
| Q92285837 | Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer |
| Q64059442 | Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms |
| Q26859201 | Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure |
| Q37361501 | Neuroendocrine differentiation in the progression of prostate cancer |
| Q28283027 | Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1 |
| Q38444947 | Neuronal Trans-Differentiation in Prostate Cancer Cells. |
| Q30441092 | Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway |
| Q37359265 | Oncogenic activation of androgen receptor |
| Q51548625 | Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. |
| Q73264118 | Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model |
| Q39020147 | Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation |
| Q24630639 | Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma |
| Q33356928 | Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle |
| Q83334262 | Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer |
| Q38265575 | Proinflammatory cytokine interleukin-6 in prostate carcinogenesis |
| Q28278555 | Prostate cancer and the met hepatocyte growth factor receptor |
| Q42370539 | Protein kinase A-mediated phosphorylation of RhoA on serine 188 triggers the rapid induction of a neuroendocrine-like phenotype in prostate cancer epithelial cells |
| Q37295602 | REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling |
| Q44615404 | Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells |
| Q38386536 | RhoGDIα suppresses growth and survival of prostate cancer cells |
| Q37784867 | Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor |
| Q38795784 | Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer |
| Q24337932 | Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors |
| Q36126540 | Soluble interleukin-6 receptor to interleukin-6 (sIL‑6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy |
| Q73431460 | Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factor |
| Q24677026 | Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer |
| Q37216993 | TRIIODOTHYRONINE ATTENUATES PROSTATE CANCER PROGRESSION MEDIATED BY β-ADRENERGIC STIMULATION |
| Q37805340 | The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities |
| Q89998761 | The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells |
| Q33835864 | The molecular basis for ethnic variation and histological subtype differences in prostate cancer |
| Q30434799 | The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor |
| Q38989505 | The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. |
| Q43207108 | The spatio-temporal dynamics of PKA activity profile during mitosis and its correlation to chromosome segregation. |
| Q44508741 | Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways |
| Q36132777 | Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells |
| Q92410960 | Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance |
| Q81140914 | [Relevance of the neuroendocrine differentiation in prostatic carcinoma] |
| Q79801048 | cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis |
| Q35083306 | pp32 reduction induces differentiation of TSU-Pr1 cells |
| Q28084943 | β-Adrenergic Receptor Signaling in Prostate Cancer |
Search more.